Components of cell-matrix linkage as potential new markers for prostate cancer by Navdaev, Alexey & Eble, Johannes Andreas
Cancers 2011, 3, 883-896; doi:10.3390/cancers3010883 
 
cancers 
ISSN 2072-6694 
www.mdpi.com/journal/cancers 
Review 
Components of Cell-Matrix Linkage as Potential New Markers 
for Prostate Cancer 
Alexey Navdaev and Johannes A. Eble * 
Center for Molecular Medicine, Deptartment Vascular Matrix Biology, Excellence Cluster Cardio-
Pulmonary System, Frankfurt University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, 
Germany; E-Mail: navdaev@med.uni-frankfurt.de 
*  Author to whom correspondence should be addressed; E-Mail: eble@med.uni-frankfurt.de;  
Tel.: +49 69 6301 87651; Fax: +49 69 6301 87656. 
Received: 25 January 2011; in revised form: 12 February 2011 / Accepted: 17 February 2011 / 
Published: 25 February 2011 
 
Abstract: Prostate cancer is one of the most common tumor diseases worldwide. Often 
being  non-aggressive,  prostate  tumors  in  these  cases  do  not  need  immediate  treatment. 
However,  about  20%  of  diagnosed  prostate  cancers  tend  to  metastasize  and  require 
treatment. Existing diagnostic methods may fail to accurately recognize the transition of a 
dormant,  non-aggressive  tumor  into  highly  malignant  prostate  cancer.  Therefore,  new 
diagnostic tools are needed to improve diagnosis and therapy of prostate carcinoma. This 
review evaluates existing methods to diagnose prostate carcinoma, such as the biochemical 
marker prostate-specific antigen (PSA), but also discusses the possibility to use the altered 
expression  of  integrins  and  laminin-332  in  prostate  carcinomas  as  diagnostic  tools  and 
therapeutic targets of prostate cancer. 
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1. Prostate Carcinoma 
Prostate carcinoma (PC) is one of the most frequent cancers diagnosed in men worldwide. For 
2010, the American Cancer Society estimated 218,000 new cases of PC with 32,000 fatal cases among 
them. In Europe 338,000 new cases of PC were diagnosed in 2008 and more than 70,000 patients died. 
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The frequency of PC is correlated to age. Nowadays, 0.1% of men in their 40s are diagnosed with PC, 
a frequency which rises to 8% at the age of 70 and older.  
In most cases, PC shows very slow or even no growth over long time periods (ten years or more) 
and many patients diagnosed with such dormant PC do not need immediate treatment like surgery or 
irradiation. If a patient is older than 70 and the probability of the patient’s death by reasons other than 
PC is relatively high, a strategy called active surveillance can be suggested [1]. In every individual 
case, the decision about the treatment strategy must be made by the attending physician, together with 
the patient, based on the clinicopathologic status of the disease. However, PC may develop a very 
aggressive  and  malignant  behavior,  which  is  characterized  by  fast  growth  of  the  primary  tumor, 
dissemination of tumor cells from the primary tumor tissue and colonization of other organs. More 
than 80% of patients with metastasizing PC have metastases in bones and lymph nodes [2]. To date, 
the nature of this phenomenon is still poorly understood. It is discussed whether a specific extracellular 
microenvironment within these organs provides an appropriate substratum to which PC metastatic cells 
adhere  to,  and  also  whether  PC  cells  develop  the  features  mimicking  osteoblasts  [3,4].  Both 
hypotheses are supported by the finding that the number of PC-derived metastases is not increased 
after surgical treatment, which is normally accompanied by a significant release of PC cells into the 
blood circulation [5]. 
The factors which determine the transition of non-aggressive dormant nodes into very aggressive, 
highly malignant PC are not yet established. Moreover, the oncogenically transformed cells may be of 
different origin, which in turn affects their malignant behavior. Prostate epithelium consists of several 
cell types, including luminal, basal, intermediate, and neuroendocrine cells. PC can originate from 
luminal cells, and is then characterized by uncontrolled growth and the absence of intermingling basal 
cells  [6].  Controversially,  a  recent  report  showed  that  human  basal  cells  underwent  oncogenic 
transformation and grew to tumors after transplantation into nude mice [7]. Therefore, it is possible that PC 
may originate from both luminal and basal cells. 
Once awakened from their dormant form, malignant cells of PC are highly aggressive and need to 
be treated. There are several different treatments for PC. In most cases the preferred treatments are 
surgical dissection and radiotherapy. In some cases a hormone therapy can be used as well, but not all 
PC are sensitive to this method. Recently, several additional therapies have been developed and tested. 
In cryosurgery, tumors are destroyed by freezing. Biotherapy (immunotherapy) boosts the patient’s 
immune system utilizing injected specific antigens. Furthermore, focused high-intensity ultrasound is 
used to treat PC. An active surveillance with routine clinical check-ups is recommended at an early 
stage of the disease when the tumor is small in size and does not show tendency to grow [8]. 
The total number of diagnosed PCs has dramatically increased over the last 20 years, whereas 
associated mortality did not change significantly. This discrepancy can be explained by the fact that 
new diagnostic methods allowed the detection of PCs at very early and curable stages, which had not 
been possible before. However, when a dormant node transforms into a malignant PC, the prognosis 
for the patient is still poor. Existing diagnostic methods often fail to detect this transition. Biochemical 
monitoring of prostate-specific antigen (PSA), together with digital rectal examination and invasive 
biopsy are the main tools to diagnose PC nowadays. 
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2. Existing Tools in PC Diagnostics 
2.1. Prostate-specific Antigen (PSA) 
In the late 1960s, a prostate specific antigen (PSA) was independently identified by several research 
groups and therefore named differently (kallikrein III, seminin, semenogelase, -seminoprotein and  
P-30 antigen). PSA is a 34 kDa serine protease which is secreted by cells of the prostate tissue. Later 
studies showed that the prostate is not the only source of PSA. However, as other organs produce PSA 
only in trace amounts, almost all PSA which circulates in the blood is the product of the prostate gland. 
The blood serum concentration of PSA is normally as low as just a few nanograms per milliliter. Yet, 
it  can  increase  considerably  or  even  by  orders  of  magnitudes  in  advanced  PC.  Hence,  PSA  was 
proposed to be a suitable marker for early detection of PC. In the USA, a PSA test has been approved 
to detect prostate cancer in men aged 50 years and older. This test was also approved to monitor 
patients with a history of PC to survey cancer recurrence. However, there is the possibility of false 
positive results, because increased blood levels of PSA do not only occur in patients suffering from 
PC, but can also be caused by prostate infection, irritation, benign prostatic hyperplasia (BPH), and 
recent ejaculation. Conversely, this test can give false negative results as well, as a relatively high 
percentage of patients with PC do not show an increased blood level of PSA [9]. These contraries 
brought up the question whether the PSA assay is a reliable diagnostic method for PC and whether it 
can  aid  to  decrease  PC-associated  mortality.  To  answer  these  questions  several  trials  have  been 
performed. Recently, results of two trials carried out in the USA and in Europe were published and 
show some controversy. In these trials, patients were annually examined for PSA blood level and 
biopsy was done for those with more than 4 ng/mL PSA. Patients with PSA levels between 3 and  
4 ng/mL were additionally checked with digital rectal exam or transrectal ultrasound. According to the 
European  data,  the  PSA-based  screening  reduced  the  PC-caused  death  rate  by  20%,  but  it  was 
associated  with  a  high  risk  of  overdiagnosis  [10].  However,  the  data  published  by  American 
researchers suggests that there is no significant decrease in PC-caused mortality in correlation with 
PSA screening [11]. These data, as well as data of several other randomized controlled  trials, are 
reviewed in a very recent article by Schrö der [12]. He reported that the thresholds of PSA blood levels, 
which are used as a cutoff in the assay, strongly influenced the screening results. He assumed that at 
the threshold of 4 ng/mL PSA about 75% of small PC escaped detection. When the threshold was 
decreased to 3 ng/mL, the percentage of non-diagnosed small PC dropped to 46%. Yet at the same 
time the number of false positive diagnoses dramatically increased. 
Therefore, despite the fact that PSA screening can be helpful in PC diagnostics, it is not sufficient to 
recognize all cases of the disease and in most cases it must be assisted by additional, non-invasive 
tests, such as digital rectal examination, transrectal ultrasound examination, and histological analyses 
of biopsies.  
2.2. Digital Rectal Examination and Transrectal Ultrasound 
Digital rectal examination detects the swelling of the prostate gland. Together with the PSA test, it 
allows identification of the disease at relatively early stages. However, small tumors, which are typical 
for early stages of PC, are rarely detected by palpation. By transrectal ultrasound (TRUS), the entire Cancers 2011, 3                               
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prostate gland can be scrutinized. Thus, the size of the prostate and the presence of tumor nodes can be 
determined. Similar to digital rectal examination, TRUS bears the risk of overlooking small clusters of 
tumor cells. Mostly, ultrasound is used to visualize and control biopsy sample collection.  
2.3. Biopsy 
Biopsy is an invasive test in which a tissue sample is obtained with a needle and subsequently 
analyzed histologically. The histological evaluation employs the Gleason grading system, which was 
established in the 1960s with some modifications in the 1970s. According to the original procedure, 
cells of the prostate tumor tissue were assigned into five grades. Highly differentiated cells which 
resemble non-transformed cells are assigned to grade 1. Non-differentiated, highly modified cells that 
are likely aggressive with a high migratory activity are assigned  to grade 5. By adding the grade 
numbers  of  the  most  common  tumor  patterns  together,  pathologists  calculated  the  Gleason  score, 
which  ranged  from  2  to  10.  The  great  technical  improvements  for  prostate  surgery,  biopsy,  and 
histology achieved in the last decades provided new data which required modification of the existing 
Gleason grading system and interpretation of the results. Thus, the International Society of Urological 
Pathology (ISUP) reached a consensus about the changes which have to occur during analysis of 
biopsy samples by the Gleason grading system. According to the new recommendations, samples with 
a  Gleason  score  of  2  should  not  be  diagnosed  as  a  low  grade  of  tumor  although  there are  some 
exceptions. When the Gleason score is 3 or 4, diagnosis can be made in rare cases and never without 
consultation. In case of a high Gleason score, the grade numbers of the most common tumor cells and 
the cells with the highest grade must be added to each other. More details on the consensus of the 
ISUP  conference  can  be  found  in  Epstein  et  al.  [13].  Furthermore,  the  changes  and  suggestions 
concerning the improvement of the Gleason grading system are summarized in a recent article by 
Epstein [14].  
Although the results of a biopsy may provide reliable data about a PC state, this method also has 
some shortcomings. Among them is the fact that the collected sample may not represent the entire 
organ. Usually, biopsy is performed under the control of TRUS, which helps to find the area where the 
sample is to be collected. However, due to an inhomogeneous distribution of malignant cells in a 
tumor tissue, the sample may not represent the actual situation in the tumor. A study by Robinson [15] 
reported that the examination of the surgically removed prostate showed a higher Gleason grade than 
was found during examination of a sample obtained by biopsy. In addition, results from histological 
examinations are subjective and depend on the personal experience of the pathologist. Therefore, the 
biopsy results could be improved by including independent quantitative markers into the PC diagnostic. 
Thus,  data  obtained  by  several  independent  tests  (i.e.,  digital  rectal  examination,  PSA  value, 
transrectal ultrasound, biopsy) are taken in account to make a decision about the treatment strategy for 
each individual patient. However, the biochemical differences between non-aggressive and aggressive 
PCs are still not entirely clear. Several studies reported that PC cells of different malignancy states 
differ  in  their  ability  to  express  proteins  involved  in  cell-matrix  interaction,  thus  influencing  cell 
migration.  These  are  integrins,  laminins  and  proteases, which  are  also  involved  in  the  process  of 
extracellular matrix remodeling and degradation. 
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3. The Extracellular Matrix and Migration of Carcinoma Cells  
Aggressive carcinoma cells migrate from the primary tumor, invade and infiltrate into neighboring 
tissues. After penetrating blood or lymphatic vessels they can colonize other organs which are located 
far  from  the  primary  tumor.  Almost  any  step  of  this  metastatic  cascade  requires  contact  to  basal 
membranes, which are penetrated by the tumor cells (Figure 1).  
Basal  membranes  (BMs)  are  thin  layers  of  extracellular  matrix  proteins  that  constitute  the 
borderline structure between connective tissue and any other tissue. Epithelial and endothelial cells are 
in close contact to the BM and are mechanically anchored via cell adhesion molecules to the BM. 
Muscle fibers, fat, and nerve cells are surrounded by a BM, which gives important environmental 
signals to these cells. Typical molecular components of the epithelial BM are collagen type IV and VII 
and laminins [16,17]. The dense meshwork of BM components is impermeable to most of the cells 
under normal conditions. Only leucocytes on their immunological patrol and pathologically malignant 
tumor cells are able to cross the BM. Key players involved in invasion of malignant cells through BMs 
are laminins (especially laminin-332), integrins, and proteases. 
Figure 1. Metastatic cascade of prostate carcinoma (PC). PC cells grow into a primary 
tumor mostly within the peripheral zone of the prostate. At an aggressive stage, carcinoma 
cells start to disseminate from the primary tumor and penetrate through a basal membrane 
and stroma. After invading blood vessels or lymphatics, carcinoma cells can reach different 
organs where they can extravasate, settle, and form metastases, most often in bones and 
lymph nodes. Characteristically, PC cells also tend to migrate along nerve bundles which 
abundantly innervate the prostate. 
 
4. Laminins 
Laminins are large glycoprotein molecules consisting of ,  and  chains. There are five , three , 
and three  chains identified to date. In different combinations they form 16 known laminin molecules, 
named according to their chain composition [18]. All laminins are characterized by a rod-like coiled-Cancers 2011, 3                               
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coil domain consisting of three chains, each folded individually into an -helix. While the coiled-coil 
domain is visualized as a long arm in electron microscopic pictures, the N-terminal domains form the 
individual three short arms of the cruciform laminin molecule. Adjacent to the C-terminal end of the 
coiled-coil domain, the large globular (G) domain is composed solely of the laminin  chain and is 
further subdivided into five homologous LG subdomains, each about 200 amino acids in length [19]. 
The first three LG subdomains, LG1, LG2, and LG3, assemble into a clover leaf-like supradomain 
structure,  which  harbors  the  putative  binding  site  for  the  laminin-binding  integrins.  However,  the 
coiled-coil domain is necessary to form or stabilize the integrin-binding site within the G-domain [20].  
Laminin-332 (previously known as laminin-5) consists of -3, -3 and -2 subunits. Laminin-332 
interacts  with  collagen  VII  of  BMs  via  a  binding  site  located  at  the  N-terminal  end  of  the  -3  
chain [21]. At the same time, it can interact with several cell surface receptors via its LG domains. 
Thereby, the  cell and its cell adhesion molecules are connected to the  BM with its force-bearing 
meshwork  of  laminins  and  collagen  IV.  Within  the  epidermal  junctional  zone,  laminin-332 
supramolecularly arranges into anchoring filaments which are found on the epithelial face of the BM 
(Lamina lucida) [22]. 
Figure 2. Structures of the non-processed laminin-332 and laminin-511. A characteristic 
hallmark of laminins is the -helical coiled-coil domain consisting of three laminin chains, 
332  or  511  for  laminin-332  and  laminin-511,  respectively.  Each  chain  can  be 
cleaved  by  several  different  proteases  with  drastic  effects  on  its  biological  functions. 
Exclusively formed by the C-terminal portion of the 3 chain, the globular (G) domain can 
be subdivided into five LG-domains, each about 200 amino acids in length. The LG4-5 
tandem domain is connected to the LG1-3 domain cluster via connecting sequence. The 
connecting sequence contains target sites for several proteases. The G-domain contains the 
putative  binding  site  for  the  integrins  31,  61,  and  64.  Secreted  laminin-332 
undergoes fast processing by proteases which cleave the LG4-5 domain of the 3 chain 
and the N-terminal domain of the 2 chain. 
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Laminin-332 can modulate migration of carcinoma cells. However, so far it has remained unclear 
whether laminin-332 accelerates or decelerates cell migration. Laminin-332 may provide strong cell 
binding  and  spreading,  thus  slowing  down  the  motility  of  epithelial  and  carcinoma  cells  [23].  In 
contrast, laminin-332 may support migration and invasion of carcinoma cells [24,25]. This discrepancy 
might  be  explained  by  the  fact  that  laminin-332  is  processed  by  different  proteases  which  are 
expressed in varying amounts by carcinoma cells. Several matrix metalloproteases (MMPs) [26] as 
well as plasmin [27,28] are responsible for these different proteolytic modifications of laminin-332, 
triggering distinct cellular functions. In addition to proteolytic modification, the effect of laminin-332 
on cellular responses can be modulated by changes in expression of integrins binding laminin-332. It is 
known that 31, 61 and 64 integrins can all bind laminin-332 but induce different cellular 
effects. The 64 integrin induces strong cell adhesion upon binding to the laminin-332, whereas the 
61 integrin promotes cell migration.  
Laminin-511 (previously known as laminin-10) consists of 5, 1, and 1 chains. The 5 chain is 
longer  than  3  due  to  several  additional  N-terminal  domains.  The  G  domain  of  laminin-511  can 
interact with 31, 61, and 64 integrins. It is not yet clear whether laminin-511 and laminin-332 
use the same or different binding sites of these receptors. The 1 and 1 chains cannot be digested by 
MT1-MMP in contrast to 3 and 2. However, MT1-MMP digests the 5-chain, which promotes PC 
cell migration [29]. Enhanced migration of carcinoma cells in this case can be explained by decreasing 
cell adhesion which slows migration. To date, there is no published data showing an active modulating 
role of laminin-511 in carcinoma cell migration as is the case for laminin-332. 
5. Integrins 
Integrins are a large family of cell surface molecules involved in adhesion, cell-cell interaction and 
regulation of cell growth and migration. They are heterodimeric molecules consisting of   and  
chains. Up to date, 18  subunits and 8  subunits have been identified which combine into 24 known 
integrins. The integrins 31, 71, 61 and 64 interact with laminins. The integrins 64 and 
31 show specificity to laminin-332 and laminin-511, whereas 71 binds to laminin 1, 2 or 5 
chain-containing laminins [30]. The integrin 61 shows a broader specificity and can bind to several 
laminin isoforms. Upon binding to laminin-332 the integrin  64 can organize hemidesmosomes, 
which  are  essential  for  stable  cell  adhesion  to  BM  [31].  The  61  integrin  is  involved  in  cell  
migration  [32].  The  role  of  the  integrin  31  in  cell  migration  is  ambivalent.  Whereas  some 
publications report that this integrin stabilizes cell adhesion and inhibits cell migration upon binding to 
laminin-332 [33], other studies ascribe a promigratory role to 31 integrin in epithelial cells [34]. 
This discrepancy cannot be explained yet and may depend on the cell type and/or additional signals 
within the cell. All integrins are transmembrane receptors and, along with other signal-transducing 
molecules, relay signals from the extracellular matrix (ECM) into the cell. Cross-talk of these signals 
with cues from growth factor receptors and further signaling results in cell-type specific reactions [35]. 
In a recent study, Edick et al. [36] showed that 31 integrin can prevent cell death of normal basal 
prostate cells by activating EGFR/Erk but not PI3-K signaling and/or autophagy activation. However, 
in PC3 cells 31 integrin provides cell survival through activation of PI3-K. In both case, signaling 
events are initiated upon binding of 31 integrin to laminin-332. It is not yet clear whether the same Cancers 2011, 3                               
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signaling  pathways  are  involved  in  PC  cell  migration  on  laminin-511  which  is  also  a  ligand  for  
31 integrin. 
6. Proteases 
To  be  able  to  move,  migrating  cells  secrete  a  number  of  proteases,  among  them  matrix 
metalloproteases (MMPs) which cleave ECM proteins, thereby breaking links between cell surface 
receptors and extracellular matrix proteins [37]. MT1-MMP, a membrane bound form of MMPs, is a 
key enzyme in the process of cancer cell invasion. MT1-MMP is responsible for cleaving basement 
membrane proteins and type I collagen in the stromal connective tissue, both necessary steps in tumor 
cell invasion. Upregulation of MT1-MMP was found in almost all invading carcinoma cells [38]. In 
addition to MMPs, several other proteases are secreted by malignant cells, e.g. matriptase and hepsin. 
Both are members of the type II transmembrane serine protease family and are abundantly produced 
by PC cells [39,40]. The metalloproteinase ADAM15 was also found to be upregulated in PC and its 
role  as  a  regulatory  component  of  tumor  progression  and  its  possible  use  as  a  biomarker  is  
discussed [41]. Despite the fact that many membrane-bound and soluble proteases are overexpressed 
by  PC,  the  MT1-MMP  probably  is  the  most  important  for  ECM  degradation  and  modulation  of 
migratory behavior of carcinoma cells.  
7. The Interplay of Laminin, Integrins and Proteases in PC Metastasis 
Enhanced expression of the laminin-332 or its individual subunits by many different carcinomas 
was shown in vitro and in vivo [42,43]. Laminin-332 stimulates carcinoma cells to form lamellipodia 
and enhances cell migration. During cell migration, cells must lose certain cell-matrix contacts and 
detach from the surrounding matrix [44]. Proteases released by migrating malignant cells can degrade 
the pericellular matrix proteins, thereby destroying firm cell anchorage points. However, complete 
detachment of cells would hamper cell migration, as the ECM meshwork also serves as a substrate to 
which cells attach and from which cells receive environmental and survival cues. Tumor cells may 
compensate for these lost contacts by enhanced secretion of extracellular proteins. In fact, binding of 
laminin-332 to 31 integrin increases cell viability by triggering PI3-K, 14-3-3, and FAK signaling 
cascades, which eventually lead to suppression of caspase activation [45]. Also, it was found that  
the  fragment  of  the  2  chain  of  laminin-332  can  bind  to  the  EGF  receptor  and  enhance  cell  
motility [46,47]. 
In  contrast  to  many  other  carcinomas,  PC  typically  produces  less  laminin-332  and  its  cognate 
receptor, 64 integrin [48,49]. In most cases of PC, laminin-332 expression is not completely absent 
because  neighboring  non-transformed  basal  prostate  cells  still  produce  laminin-332,  which  allows 
prostate carcinoma cells to survive and migrate [50].  
In a recent study, a subpopulation of cells named TEM4-18 was isolated from PC-3, a prostate 
carcinoma cell line. This newly identified subpopulation of cells is characterized by overexpression of 
ZEB-1,  a  known  regulator  of  epithelial-to-mesenchymal  transition,  and  was  able  to  intra-  and 
extravasate through endothelial barriers more efficiently than parental PC-3 cells. Also, TEM4-18 
exhibited enhanced metastatic colonization in a murine in vivo model. Surprisingly, TEM4-18 cells 
were less invasive than parental PC-3 cells in in vitro assays involving matrix barriers [51]. In the most Cancers 2011, 3                               
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recent  work,  it  was  shown  that  highly  aggressive  TEM4-18  cells  strongly  reduce  laminin-332 
expression in comparison to less aggressive PC-3 cells which still produce a moderate level of this 
protein. The invasiveness of TEM4-18 cells in vitro was restored when exogenous laminin-332 was 
added  or  when  cells  were  co-cultured  with  laminin-332  secreting  cells  [52].  Thus,  these  highly 
aggressive PC cells still needed interaction with laminin-332 to be able to migrate despite the fact that 
they did not produce it by themselves.  
This discrepancy is nevertheless well correlated with data concerning the role of laminin-332 in 
carcinoma cell migration. On the one hand, it is shown that laminin-332 is over-expressed by many 
carcinomas  and  accelerates  migration  of  malignant  cells.  On  the  other  hand,  numerous  accounts 
confirm reduction of laminin-332 expression by PC. It can be assumed that highly invasive PC cells, 
which  show  reduced  expression  of  laminin-332  during  migration  can  use  the  protein  secreted  by 
neighboring non-invasive cells. Moreover, during migration aggressive PC cells can use laminin-511 
whose expression by these cells is not decreased. Also, migration of PC cells along the nerve bundles, 
which have laminin-511 enriched basal membranes, is well known. 
The mechanism regulating the expression of laminin-332 in PC cells is not fully understood. ZEB1, 
a regulator of epithelial-to-mesenchymal transition, regulates laminin-332 and 4 integrin expression [52]. 
However, other, still unknown factors may also affect laminin-332 synthesis. Moreover, the strong 
lack of laminin-332 may be aggravated by its degradation by proteases. Increased mobility of PC cells 
is likely related to the proteolytic processing of laminin-332 by secreted proteases [40,53].  
Laminin-511 is abundant in basement membranes ensheathing nerves, which numerously innervate 
the prostate gland [32,54]. Typically, PC cells disseminate from the peripheral zone of the gland along 
nerve bundles which reach the prostate capsule [55,56]. During this perineural invasion (PNI) several 
mediators and chemokines are released by both the cancer and the nerve cells which stimulate tumor cell 
survival and facilitate their migration [57]. Laminin-511 of the perinerium is recognized by 61 integrin, 
and thus plays an important role in PNI [32]. The expression of laminin-511 is not altered in prostate 
cancer but its ability to interact with integrins can be strongly decreased due to 5 chain processing by 
MT1-MMP which is over-expressed by carcinoma cells [29]. 
In contrast to laminin-332 and its cognate receptor 64 integrin, the expression of the laminin 
receptor 61 is unaltered or even upregulated [58]. The 61 integrin binds to laminin-511 and 
mediates cell migration [30]. In PC, 61 integrin expression is strongly reduced while the 61 
integrin  level  does  not  changed.  There  while,  the  question  about  31  integrin  expression in  PC 
remains open. There are only few articles regarding 31 expression with very controversial results. In 
a recent article by Schmelz et al. [59], the authors reported that low Gleason sum score is associated 
with increased expression of the integrin. The samples with a high Gleason sum score showed very 
low  or  even  an  absence  of  the  31  expression.  In  another  article,  the  authors  conclude  that  an 
increase in 31 expression is typical for highly aggressive PC cells and associated with a higher risk 
for cancer recurrence [60]. Thus, 31 integrin expression by PC cells requires further examination. 
8. Conclusions 
During  transformation  from  a  non-invasive  to  a  highly  malignant  phenotype,  PC  changes  the 
expression levels of several proteins involved in cell-matrix interactions. The laminin-332 level is Cancers 2011, 3                               
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down-regulated in contrast to the unaltered expression of laminin-511. The integrin 64 expression is 
down-regulated  while  integrin  61  is  not  changed  or  is  even  upregulated.  There  is  no  uniform 
opinion about the expression of integrin 31 by PC cells and this issue needs further investigation. 
PC cells show elevated level of MT1-MMP and secreted matriptase. Quantification of these changes 
could provide a PC-typical tumor signature and may improve the diagnostics of PC, which so far has 
been based on histological examination of biopsies and the Gleason score calculation, along with the 
blood  marker  PSA.  Moreover,  understanding  the  underlying  mechanisms  of  how  these  molecules 
target  and  mediate  migration,  invasion,  and  progression  of  prostate  cancer  cells  may  open  new 
pharmaceutical avenues to treat PC. 
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